Inicure particppated in the AMR conference i Basel meeting research collaborators, service providers and potential future commercial partners for Inicures anti- infective candidate therapies,
A great meeting with Incate advisor Peter Seiler to start an interesting development journey with support from Incate https://lnkd.in/eB69c6tr
Inicure has been awarded support from the INCATE network (Incubator for Antibacterial Therapies in Europe). Access to advice and the network of partners, including industry and health providers, will truly support and boost our work to combat drug-resistant bacterial infections.
The EIC-Transition proposal — iCURE “Novel small molecule FPR1 agonists for treating antibiotic-resistant and chronic bacterial infections” coordinated by Inicure and submitted together with our partners at Swansea University, Queen Mary University of London and LIOS received very high ranking in the competitive evaluation process. Although the project was eventually not granted, we are super proud to have received the Seal of Excellence by the European Commission!
Inicure was pitched by CEO Peter Olofsson-Sahl at GoWest – Nordic capital 28-29 January 2026. Inicures approach to combat the threat from AMR received great attention from investors and future partners. So many interesting connections, fruitful discussions, and meetings with old and new friends.
Invited as presenter at the Immunotherapies & Innovations for Infectious Diseases Congress (#I4ID2025) – in Lyon, CEO of Inicure Peter Olofsson-Sahl presetnerd our lates progress, including lead optimisation running at #ScilifeLAB.
This was a great opportunity to update contacts with some of our future R&D partners, and listen to the support provided by CARB-X, Incate and the ID cluster and the listen to updates on the increasing problem with AMR, lack of effective therapies and urge for novel actions and therapies to combat the progression of the global number One medical threat of increasing antibiotic resistance
Chairman Dr Sara Malcus and CEO Peter Olofsson-Sahl participated in the Nordic Life Science days. Reconnecting with several of or ker research partners, analysing potential future CRO provides and advisors for CMC, pre-clinical safety and routes to clinical studies as well as initiating relation with seed investors and corporate finance.
Peter Olofsson- Sahl participated in the @GUventure organised pitching event for investors taking place to specially invited investors in innovative life science technologies at Gothia Tower
Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at University West, has received support from the national drug discovery platform at Scilife LAB. The lead candidates have shown strong potential, particularly for severe infections like chronic urinary tract and lung infections.With the help of DDD, they will focus on optimizing these compounds to meet industry standards. Bringing them closer to clinical use as a much-needed alternative for life-threatening infections. The current project is going very well and we have alreday treached some very promising improved pre-CD molecules and hope to be able to nominate or CD in mid 2026.
CEO, Peter Olofsson-Sahl presented Inicure at the #BiotechHanse event as innovative Swedish Life Science innovation for Sweden-Germany collaboration and partnership opportunities
As partner to the IMPACT project led by University Southern Denmark (SDU) and professor Thomas Andersen, Inucure is partner of the granted project IMPACT ””IMproving the Pig biomedical model for ACcelerating Translational research in anti-infection drugs and prophylaxes” supported by the Danish Open Discovery Innovation Network (ODIN) that is funded by the Novo Nordisk Foundation.
The IMPACT project (2025-2028) aims to improve the outcome of preclinical trials in pigs by establishing an assay platform for monitoring disease and immunogenicity status in the pig.
Inicure have been granted support from VINNOVA Planeringsbidrag to improve our EIC Transition proposal. Inicure is coordinating a consortia for collaboration between LIOS, Queen Mary Hospital University London and Swansea University for a joing program to characterise and mature Inicures candidate therapies to boost the Innate immune system as novel therapy to cure resistant infections in a joint project called iCURE. The EIC Transition application will be competed and submitted in mid september 2025.